EU pharmacovigilance law introduces 'more pain than gain', say companies
This article was originally published in SRA
Executive Summary
The two main objectives of the EU pharmacovigilance legislation were to strengthen and rationalize existing drug surveillance systems. After almost a year of the law coming into effect, many drug companies believe that the tenet of rationalization has been somewhat lost along the way.